A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants
NCT ID: NCT00000878
Last Updated: 2021-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
26 participants
INTERVENTIONAL
2001-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Most HIV-positive pregnant women usually take the anti-HIV drug zidovudine (ZDV) to treat HIV and reduce the chances of giving HIV to their babies. It recently has been shown that a combination of drugs may be more effective than ZDV alone. This study tests the effectiveness of combinations of ZDV, d4T, and 3TC.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Two cohorts of women and infants are enrolled in this study. The first five mother/infant pairs enrolled comprise Group I. Mothers enrolled in this group must allow their infants to receive ZDV. Eight mother/infant pairs are then enrolled in Group II; Group II infants are allocated into two groups: those whose mothers allow the administration of ZDV (Group IIA) and those whose mothers do not (Group IIB).
Group I:
Women:
Beginning at a minimum of 14 weeks gestation:
1. Oral d4T until the start of active labor.
2. Oral 3TC.
At the start of active labor (defined as regular uterine contractions resulting in cervical dilation \[3-4 cm\] and effacement \[50-60%\]) and during delivery:
1. d4T administered IV as a loading dose followed by a continuous infusion until the umbilical cord is clamped.
2. Oral 3TC if patient's previous dose of 3TC was administered at least 0.5h prior to onset of labor and additional dose of 3TC is administered and the time until next dose is scheduled accordingly.
Infants:
1. d4T as a single oral dose on Day 6 (+/- 2 days) and on Day 42 (this dose can be given between Days 35 and 42, inclusive).
2. Oral ZDV (or IV if unable to take oral dosing) for 6 weeks, beginning a maximum of 12 hours after birth.
3. 3TC for 6 weeks, beginning a maximum of 12 hours after birth.
Group II:
Women:
Beginning at a minimum of 14 weeks gestation:
1. Oral d4T until the umbilical cord is clamped.
2. Oral 3TC.
At the start of active labor and through delivery:
Oral d4T and 3TC as above. If the last doses of d4T and 3TC were given at least 0.5 hours prior to onset of active labor, an additional dose of d4T and 3TC is given and repeated every 12 hours.
Infant Group IIA:
1. d4T as a single oral dose on Day 6 (+/- 2 days) and on Day 42 (this dose can be given between Days 35 and 42, inclusive).
2. Oral ZDV (or IV if unable to tolerate oral dosing) for 6 weeks, beginning a maximum of 12 hours after birth.
3. 3TC for 6 weeks, beginning a maximum of 12 hours after birth.
Infant Group IIB:
Beginning a maximum of 12 hours after birth:
1. d4T for 6 weeks.
2. 3TC for 6 weeks. \[AS PER AMENDMENT 9/15/97: If tolerated, infants continue on protocol treatment to 6 weeks of age. At 6 weeks, infants should receive standard care, including PCP prophylaxis, from an HIV specialist/pediatrician. HIV-infected infants are offered ACTG trial enrollment or open-label treatment based on best clinical judgment of their physician.\] \[AS PER AMENDMENT 2/19/99: Patients who prematurely discontinue study treatment should continue to be followed on study for the duration of the study.\]
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lamivudine
Stavudine
Zidovudine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are HIV-positive.
* Are at least 13 years old (need consent of parent or guardian if under 18).
* Are unable to or refuse to take ZDV or the woman's doctor says that she should take d4T.
* Are 14 to 34 weeks pregnant.
Exclusion Criteria
* Have a history of peripheral neuropathy.
* Have an active opportunistic infection and/or serious bacterial infection within 14 days of study entry.
* Have severe diarrhea.
* Are allergic to d4T or 3TC.
* Use illicit drugs or abuse alcohol.
* Are taking anti-HIV drugs other than study medications.
* Are planning to breast-feed.
* Are having a problem pregnancy (baby is not developing correctly or will not survive birth) or have had pregnancy complications in the past.
* Babies will not be eligible for this study if they:
* Are unable to take medications by mouth for more than 72 hours.
* Have severe birth defects or other life-threatening conditions.
* Are underweight (less than 2 kg).
13 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nancy Wade
Role: STUDY_CHAIR
Sandra Burchett
Role: STUDY_CHAIR
Salih Yasin
Role: STUDY_CHAIR
Jash Unadkat
Role: STUDY_CHAIR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Los Angeles County - USC Med Ctr
Los Angeles, California, United States
UCLA Med Ctr / Pediatric
Los Angeles, California, United States
Harbor - UCLA Med Ctr / UCLA School of Medicine
Los Angeles, California, United States
Howard Univ Hosp
Washington D.C., District of Columbia, United States
Univ of Florida Health Science Ctr / Pediatrics
Jacksonville, Florida, United States
Univ of Miami / Jackson Memorial Hosp
Miami, Florida, United States
Univ of Miami (Pediatric)
Miami, Florida, United States
Univ of Chicago Children's Hosp
Chicago, Illinois, United States
Children's Hosp of Boston
Boston, Massachusetts, United States
Brigham and Women's Hosp
Boston, Massachusetts, United States
Univ of Medicine & Dentistry of New Jersey / Univ Hosp
Newark, New Jersey, United States
Children's Hosp at Albany Med Ctr
Albany, New York, United States
SUNY Health Sciences Ctr at Syracuse / Pediatrics
Syracuse, New York, United States
Duke Univ Med Ctr
Durham, North Carolina, United States
Temple Univ School of Medicine
Philadelphia, Pennsylvania, United States
Regional Med Ctr at Memphis
Memphis, Tennessee, United States
Saint Jude Children's Research Hosp of Memphis
Memphis, Tennessee, United States
Children's Hospital & Medical Center / Seattle ACTU
Seattle, Washington, United States
Univ of Puerto Rico / Univ Children's Hosp AIDS
San Juan, , Puerto Rico
San Juan City Hosp
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11304
Identifier Type: REGISTRY
Identifier Source: secondary_id
PACTG 332
Identifier Type: -
Identifier Source: secondary_id
ACTG 332
Identifier Type: -
Identifier Source: org_study_id